Greenwich Lifesciences Inc (GLSI) - Total Liabilities
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has total liabilities worth $1.62 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GLSI cash flow conversion to assess how effectively this company generates cash.
Greenwich Lifesciences Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Greenwich Lifesciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Greenwich Lifesciences Inc net assets for net asset value and shareholders' equity analysis.
Greenwich Lifesciences Inc Competitors by Total Liabilities
The table below lists competitors of Greenwich Lifesciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianyu Ecology & Landscape Co
SHG:603717
|
China | CN¥2.29 Billion |
|
Pengana Private Equity Trust
AU:PE1
|
Australia | AU$15.18 Million |
|
RoadMain T Co Ltd
SHG:603860
|
China | CN¥115.80 Million |
|
Favite Inc
TW:3535
|
Taiwan | NT$616.49 Million |
|
Borosil Limited
NSE:BOROLTD
|
India | Rs3.28 Billion |
|
Orient Cement Limited
NSE:ORIENTCEM
|
India | Rs9.01 Billion |
|
Campine
BR:CAMB
|
Belgium | €133.32 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Greenwich Lifesciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Greenwich Lifesciences Inc (GLSI) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Greenwich Lifesciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Greenwich Lifesciences Inc (2017–2024)
The table below shows the annual total liabilities of Greenwich Lifesciences Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.56 Million | +429.79% |
| 2023-12-31 | $294.41K | +11.98% |
| 2022-12-31 | $262.90K | -31.74% |
| 2021-12-31 | $385.17K | -63.16% |
| 2020-12-31 | $1.05 Million | -24.08% |
| 2019-12-31 | $1.38 Million | -86.54% |
| 2018-12-31 | $10.23 Million | +19.53% |
| 2017-12-31 | $8.56 Million | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also de… Read more